Journal article
Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease
Abstract
OBJECTIVES: (1) Describe how the risk of major adverse cardiovascular events (MACE) in individuals with chronic myeloid leukaemia (CML) has evolved; (2) evaluate the risk of MACE associated with the prescription of different CML tyrosine kinase inhibitors (TKI).
METHODS: A population-based retrospective study including all patients (n=4238) diagnosed with CML in Ontario, Canada between 1986 and 2017 and and age-matched and sex-matched …
Authors
Leong D; Aghel N; Hillis C; Siegal D; Karampatos S; Rangarajan S; Pond G; Seow H
Journal
Heart, Vol. 107, No. 8, pp. 667–673
Publisher
BMJ
Publication Date
April 2021
DOI
10.1136/heartjnl-2020-318251
ISSN
1355-6037